Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
06 Setembro 2023 - 8:00AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing
company utilizing its proprietary ARCUS® platform to develop in
vivo gene editing therapies, today announced that members of
management will participate in the following investor conferences
in the month of September:
H.C. Wainwright Annual Global Investment Conference 2023
Date: September 11, 2023 Time: Available on-demand at 7:00 am
ET
Jefferies Gene Editing/Gene Therapy Summit Date:
September 27, 2023 Time: 8:30 am ET
Live webcasts will be accessible on Precision’s website in the
Investors section under Events & Presentations at
https://investor.precisionbiosciences.com/events-and-presentations.
An archived replay will be available for approximately 30 days
following the event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a biotechnology company dedicated
to improving life (DTIL) with its novel and proprietary ARCUS®
genome editing platform. ARCUS is a highly precise and versatile
genome editing platform that was designed with therapeutic safety,
delivery, and control in mind. Using ARCUS, the Company’s pipeline
consists of in vivo gene editing candidates designed to cure
genetic and infectious diseases where no adequate treatments exist.
For more information about Precision BioSciences, please visit
www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906587845/en/
Mei Burris Director, Investor Relations and Finance
Mei.Burris@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024